



May 12, 2015

Securities and Exchange Commission  
100 F. Street, NE  
Washington, D.C. 20549

**Re: DelMar Pharmaceuticals, Inc.  
Registration Statement on Form S-1  
File No. 333-203357**

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group LLC and Roth Capital Partners, LLC, as joint book running managers and representative of the underwriters, hereby request acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m., Washington D.C. time, on Wednesday May 13, 2015, or as soon thereafter as practicable.

The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

- (i) Date of preliminary prospectus: May 7, 2015
- (ii) Dates of distribution: May 8 – May 11, 2015
- (iii) Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 4
- (iv) Number of prospectuses so distributed: approximately 580

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

Very truly yours,

**MAXIM GROUP LLC**

/s/ Clifford A. Teller

---

Name: Clifford A. Teller  
Title: Executive Managing Director,  
Head of Investment Banking

**ROTH CAPITAL PARTNERS, LLC**

/s/ Aaron M. Gurewitz

---

Name: Aaron M. Gurewitz  
Title: Head of Equity Capital Markets